On May 12, 2025, Biogen Inc. completed the issuance and sale of $1.75 billion aggregate principal amount of senior unsecured notes. The offering consisted of $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055. This follows the company's entry into an underwriting agreement on May 6, 2025, with BofA Securities, Inc., Citigroup Global Markets Inc., and J.P. Morgan Securities LLC. The net proceeds from this offering, combined with cash on hand, will be used to fully retire Biogen's outstanding 4.050% Senior Notes due 2025, which had an outstanding amount of $1.75 billion as of March 31, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.